RERE

Across TCGA pan-cancer cohorts, RERE Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RERE data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RERE Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RERE expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, SCLC, and UCEC are the cancer types where RERE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.300	0.693	.019	18	view →
SCLC	OS	Median	II,III,IV	0.082	0.648	<.001	18	view →
UCEC	DFS	Median	All	0.979	0.600	<.001	18	view →
SARC	DFS	Median	All	0.197	0.612	.034	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RERE–OV (OS)

Open the OV breakdown →